决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Membrane-Bound Multimodal Plasmonic Transducers for Noninvasive, In Situ Monitoring and Control of CAR T Cells Against Heterogeneous Solid Tumors.
这些换能器在超过 20 mJ cm -2 的激光通量下表现出约 90% 的吸收效率和光稳定性,在多个激光循环中提供光声和热响应。
针对异质性实体瘤的 CAR T 细胞的无创监测与控制,仍是理解和改善治疗应答方面的主要挑战。为解决这一问题,开发了膜结合型等离激元换能器,其由各向异性框架中等离激元耦合的金纳米球组成,用于多模态光声成像以及 CAR T 细胞活性的局部热调控。这些换能器在超过 20 mJ cm -2 的激光能量密度下表现出约 90% 的吸收效率和光稳定性,可在多个激光循环中提供光声和热响应。因此,CAR T 细胞上的膜结合型换能器能够在激光激发下实现光声与热响应,而不损害关键细胞功能。在异质性 HER2 表达的乳腺肿瘤模型中,纵向光声成像能够基于早期 T 细胞转运对肿瘤进行前瞻性分层,以高灵敏度和高特异性预测应答者与无应答者。此外,换能器介导的对瘤内 CAR T 细胞的热调控——这些 CAR T 细胞经工程化改造、携带可分泌 T 细胞衔接器的热遗传回路——将细胞毒性重定向至抗原阴性肿瘤,克服了抗原逃逸,从而增强了治疗。综上所述,我们展示了一种通过膜结合型多模态换能器无创监测和控制 CAR T 细胞以对抗异质性实体瘤的策略。
Noninvasive monitoring and control of CAR T cells against heterogeneous solid tumors remain major challenges in understanding and improving treatment response. To address this, membrane-bound plasmonic transducers, composed of plasmonically coupled gold nanospheres in an anisotropic framework, were developed for multimodal photoacoustic imaging and localized thermal modulation of CAR T cell activity. These transducers exhibit approximately 90% absorption efficiency and photostability under laser fluences exceeding 20 mJ cm -2 , delivering photoacoustic and thermal responses over multiple lasing cycles. Membrane-bound transducers on CAR T cells thus enable photoacoustic and thermal responsiveness upon laser excitation without compromising key cellular functions. In heterogeneous HER2-expressing breast tumor models, longitudinal photoacoustic imaging enabled prospective stratification of tumors based on early T cell trafficking, predicting responders versus nonresponders with high sensitivity and specificity. Moreover, transducer-mediated thermal modulation of intratumoral CAR T cells engineered with thermogenetic circuits to secrete T cell engagers redirected cytotoxicity toward antigen-negative tumors, overcoming antigen escape and consequently enhancing therapy. Taken together, we demonstrate a strategy to noninvasively monitor and control CAR T cells against heterogeneous solid tumors via membrane-bound multimodal transducers.
MEMBER ACCOUNT
登录成功会直接打开下一页。